Loading…
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion
•Outcome was studied of del 5q myelodysplastic syndrome patients undergoing allogeneic transplantation.•Patients with
Saved in:
| Published in: | Biology of blood and marrow transplantation 2018-03, Vol.24 (3), p.507-513 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c522t-b55f030d2d192ad416f78b575cbdaa7916661d91c7294a73a140554e4fe5245a3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c522t-b55f030d2d192ad416f78b575cbdaa7916661d91c7294a73a140554e4fe5245a3 |
| container_end_page | 513 |
| container_issue | 3 |
| container_start_page | 507 |
| container_title | Biology of blood and marrow transplantation |
| container_volume | 24 |
| creator | Garderet, Laurent Ziagkos, Dimitris van Biezen, Anja Iacobelli, Simona Finke, Jürgen Maertens, Johan Volin, Liisa Ljungman, Per Chevallier, Patrice Passweg, Jakob Schaap, Nicolaas Beelen, Dietrich Nagler, Arnon Blaise, Didier Poiré, Xavier Yakoub-Agha, Ibrahim Lenhoff, Stig Craddock, Charles Schots, Rik Rambaldi, Alessandro Sanz, Jaime Jindra, Pavel Mufti, Ghulam J. Robin, Marie Kröger, Nicolaus |
| description | •Outcome was studied of del 5q myelodysplastic syndrome patients undergoing allogeneic transplantation.•Patients with |
| doi_str_mv | 10.1016/j.bbmt.2017.11.017 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_492209</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1083879117308637</els_id><sourcerecordid>1971681155</sourcerecordid><originalsourceid>FETCH-LOGICAL-c522t-b55f030d2d192ad416f78b575cbdaa7916661d91c7294a73a140554e4fe5245a3</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhiMEoqXwBzggH7kkeJzYjiUu1fIpFYFEOSLLsSfgJYm3tpdq_z2OdltOcJrR6HnG1rxV9RxoAxTEq20zDHNuGAXZADSlPKjOgbO2FrwVD0tP-7bupYKz6klKW0qp7Hr1uDpjCpSgsj-vvl9OU_iBC3pLvmacyQaniVxHs6TdZJZssg8LGUMknw44BXdYxymv9GFxMcxIvhQGl5zIrc8_iSH8hrzBCVfxafVoNFPCZ6d6UX179_Z686G--vz-4-byqracsVwPnI-0pY45UMy4DsQo-4FLbgdnTPm_EAKcAiuZ6oxsDXSU8w67ETnruGkvqvq4N93ibj_oXfSziQcdjNen0a_Soe4UY1QVXv2T38Xg_kp3IrSyFyB6WdyXR7eAN3tMWc8-2XI1s2DYJw1KFg6A84KyI2pjSCnieP8QUL1GqLd6jVCvEWoAXUqRXpz274cZ3b1yl1kBXh8BLBf97THqZEsAFp2PaLN2wf9v_x-asK5z</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1971681155</pqid></control><display><type>article</type><title>Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion</title><source>ScienceDirect Journals</source><creator>Garderet, Laurent ; Ziagkos, Dimitris ; van Biezen, Anja ; Iacobelli, Simona ; Finke, Jürgen ; Maertens, Johan ; Volin, Liisa ; Ljungman, Per ; Chevallier, Patrice ; Passweg, Jakob ; Schaap, Nicolaas ; Beelen, Dietrich ; Nagler, Arnon ; Blaise, Didier ; Poiré, Xavier ; Yakoub-Agha, Ibrahim ; Lenhoff, Stig ; Craddock, Charles ; Schots, Rik ; Rambaldi, Alessandro ; Sanz, Jaime ; Jindra, Pavel ; Mufti, Ghulam J. ; Robin, Marie ; Kröger, Nicolaus</creator><creatorcontrib>Garderet, Laurent ; Ziagkos, Dimitris ; van Biezen, Anja ; Iacobelli, Simona ; Finke, Jürgen ; Maertens, Johan ; Volin, Liisa ; Ljungman, Per ; Chevallier, Patrice ; Passweg, Jakob ; Schaap, Nicolaas ; Beelen, Dietrich ; Nagler, Arnon ; Blaise, Didier ; Poiré, Xavier ; Yakoub-Agha, Ibrahim ; Lenhoff, Stig ; Craddock, Charles ; Schots, Rik ; Rambaldi, Alessandro ; Sanz, Jaime ; Jindra, Pavel ; Mufti, Ghulam J. ; Robin, Marie ; Kröger, Nicolaus</creatorcontrib><description>•Outcome was studied of del 5q myelodysplastic syndrome patients undergoing allogeneic transplantation.•Patients with <5% bone marrow blasts and female recipients have the best prognosis.•Additional cytogenetic abnormalities do not influence the outcome.
The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P < .001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41 to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q) abnormality.</description><identifier>ISSN: 1083-8791</identifier><identifier>ISSN: 1523-6536</identifier><identifier>EISSN: 1523-6536</identifier><identifier>DOI: 10.1016/j.bbmt.2017.11.017</identifier><identifier>PMID: 29196078</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Allogeneic stem cell transplantation ; del (5q) ; MDS ; Medicin och hälsovetenskap</subject><ispartof>Biology of blood and marrow transplantation, 2018-03, Vol.24 (3), p.507-513</ispartof><rights>2017 The American Society for Blood and Marrow Transplantation</rights><rights>Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c522t-b55f030d2d192ad416f78b575cbdaa7916661d91c7294a73a140554e4fe5245a3</citedby><cites>FETCH-LOGICAL-c522t-b55f030d2d192ad416f78b575cbdaa7916661d91c7294a73a140554e4fe5245a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29196078$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:137861687$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Garderet, Laurent</creatorcontrib><creatorcontrib>Ziagkos, Dimitris</creatorcontrib><creatorcontrib>van Biezen, Anja</creatorcontrib><creatorcontrib>Iacobelli, Simona</creatorcontrib><creatorcontrib>Finke, Jürgen</creatorcontrib><creatorcontrib>Maertens, Johan</creatorcontrib><creatorcontrib>Volin, Liisa</creatorcontrib><creatorcontrib>Ljungman, Per</creatorcontrib><creatorcontrib>Chevallier, Patrice</creatorcontrib><creatorcontrib>Passweg, Jakob</creatorcontrib><creatorcontrib>Schaap, Nicolaas</creatorcontrib><creatorcontrib>Beelen, Dietrich</creatorcontrib><creatorcontrib>Nagler, Arnon</creatorcontrib><creatorcontrib>Blaise, Didier</creatorcontrib><creatorcontrib>Poiré, Xavier</creatorcontrib><creatorcontrib>Yakoub-Agha, Ibrahim</creatorcontrib><creatorcontrib>Lenhoff, Stig</creatorcontrib><creatorcontrib>Craddock, Charles</creatorcontrib><creatorcontrib>Schots, Rik</creatorcontrib><creatorcontrib>Rambaldi, Alessandro</creatorcontrib><creatorcontrib>Sanz, Jaime</creatorcontrib><creatorcontrib>Jindra, Pavel</creatorcontrib><creatorcontrib>Mufti, Ghulam J.</creatorcontrib><creatorcontrib>Robin, Marie</creatorcontrib><creatorcontrib>Kröger, Nicolaus</creatorcontrib><title>Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion</title><title>Biology of blood and marrow transplantation</title><addtitle>Biol Blood Marrow Transplant</addtitle><description>•Outcome was studied of del 5q myelodysplastic syndrome patients undergoing allogeneic transplantation.•Patients with <5% bone marrow blasts and female recipients have the best prognosis.•Additional cytogenetic abnormalities do not influence the outcome.
The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P < .001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41 to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q) abnormality.</description><subject>Allogeneic stem cell transplantation</subject><subject>del (5q)</subject><subject>MDS</subject><subject>Medicin och hälsovetenskap</subject><issn>1083-8791</issn><issn>1523-6536</issn><issn>1523-6536</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kU1v1DAQhiMEoqXwBzggH7kkeJzYjiUu1fIpFYFEOSLLsSfgJYm3tpdq_z2OdltOcJrR6HnG1rxV9RxoAxTEq20zDHNuGAXZADSlPKjOgbO2FrwVD0tP-7bupYKz6klKW0qp7Hr1uDpjCpSgsj-vvl9OU_iBC3pLvmacyQaniVxHs6TdZJZssg8LGUMknw44BXdYxymv9GFxMcxIvhQGl5zIrc8_iSH8hrzBCVfxafVoNFPCZ6d6UX179_Z686G--vz-4-byqracsVwPnI-0pY45UMy4DsQo-4FLbgdnTPm_EAKcAiuZ6oxsDXSU8w67ETnruGkvqvq4N93ibj_oXfSziQcdjNen0a_Soe4UY1QVXv2T38Xg_kp3IrSyFyB6WdyXR7eAN3tMWc8-2XI1s2DYJw1KFg6A84KyI2pjSCnieP8QUL1GqLd6jVCvEWoAXUqRXpz274cZ3b1yl1kBXh8BLBf97THqZEsAFp2PaLN2wf9v_x-asK5z</recordid><startdate>20180301</startdate><enddate>20180301</enddate><creator>Garderet, Laurent</creator><creator>Ziagkos, Dimitris</creator><creator>van Biezen, Anja</creator><creator>Iacobelli, Simona</creator><creator>Finke, Jürgen</creator><creator>Maertens, Johan</creator><creator>Volin, Liisa</creator><creator>Ljungman, Per</creator><creator>Chevallier, Patrice</creator><creator>Passweg, Jakob</creator><creator>Schaap, Nicolaas</creator><creator>Beelen, Dietrich</creator><creator>Nagler, Arnon</creator><creator>Blaise, Didier</creator><creator>Poiré, Xavier</creator><creator>Yakoub-Agha, Ibrahim</creator><creator>Lenhoff, Stig</creator><creator>Craddock, Charles</creator><creator>Schots, Rik</creator><creator>Rambaldi, Alessandro</creator><creator>Sanz, Jaime</creator><creator>Jindra, Pavel</creator><creator>Mufti, Ghulam J.</creator><creator>Robin, Marie</creator><creator>Kröger, Nicolaus</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>20180301</creationdate><title>Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion</title><author>Garderet, Laurent ; Ziagkos, Dimitris ; van Biezen, Anja ; Iacobelli, Simona ; Finke, Jürgen ; Maertens, Johan ; Volin, Liisa ; Ljungman, Per ; Chevallier, Patrice ; Passweg, Jakob ; Schaap, Nicolaas ; Beelen, Dietrich ; Nagler, Arnon ; Blaise, Didier ; Poiré, Xavier ; Yakoub-Agha, Ibrahim ; Lenhoff, Stig ; Craddock, Charles ; Schots, Rik ; Rambaldi, Alessandro ; Sanz, Jaime ; Jindra, Pavel ; Mufti, Ghulam J. ; Robin, Marie ; Kröger, Nicolaus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c522t-b55f030d2d192ad416f78b575cbdaa7916661d91c7294a73a140554e4fe5245a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Allogeneic stem cell transplantation</topic><topic>del (5q)</topic><topic>MDS</topic><topic>Medicin och hälsovetenskap</topic><toplevel>online_resources</toplevel><creatorcontrib>Garderet, Laurent</creatorcontrib><creatorcontrib>Ziagkos, Dimitris</creatorcontrib><creatorcontrib>van Biezen, Anja</creatorcontrib><creatorcontrib>Iacobelli, Simona</creatorcontrib><creatorcontrib>Finke, Jürgen</creatorcontrib><creatorcontrib>Maertens, Johan</creatorcontrib><creatorcontrib>Volin, Liisa</creatorcontrib><creatorcontrib>Ljungman, Per</creatorcontrib><creatorcontrib>Chevallier, Patrice</creatorcontrib><creatorcontrib>Passweg, Jakob</creatorcontrib><creatorcontrib>Schaap, Nicolaas</creatorcontrib><creatorcontrib>Beelen, Dietrich</creatorcontrib><creatorcontrib>Nagler, Arnon</creatorcontrib><creatorcontrib>Blaise, Didier</creatorcontrib><creatorcontrib>Poiré, Xavier</creatorcontrib><creatorcontrib>Yakoub-Agha, Ibrahim</creatorcontrib><creatorcontrib>Lenhoff, Stig</creatorcontrib><creatorcontrib>Craddock, Charles</creatorcontrib><creatorcontrib>Schots, Rik</creatorcontrib><creatorcontrib>Rambaldi, Alessandro</creatorcontrib><creatorcontrib>Sanz, Jaime</creatorcontrib><creatorcontrib>Jindra, Pavel</creatorcontrib><creatorcontrib>Mufti, Ghulam J.</creatorcontrib><creatorcontrib>Robin, Marie</creatorcontrib><creatorcontrib>Kröger, Nicolaus</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>Biology of blood and marrow transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garderet, Laurent</au><au>Ziagkos, Dimitris</au><au>van Biezen, Anja</au><au>Iacobelli, Simona</au><au>Finke, Jürgen</au><au>Maertens, Johan</au><au>Volin, Liisa</au><au>Ljungman, Per</au><au>Chevallier, Patrice</au><au>Passweg, Jakob</au><au>Schaap, Nicolaas</au><au>Beelen, Dietrich</au><au>Nagler, Arnon</au><au>Blaise, Didier</au><au>Poiré, Xavier</au><au>Yakoub-Agha, Ibrahim</au><au>Lenhoff, Stig</au><au>Craddock, Charles</au><au>Schots, Rik</au><au>Rambaldi, Alessandro</au><au>Sanz, Jaime</au><au>Jindra, Pavel</au><au>Mufti, Ghulam J.</au><au>Robin, Marie</au><au>Kröger, Nicolaus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion</atitle><jtitle>Biology of blood and marrow transplantation</jtitle><addtitle>Biol Blood Marrow Transplant</addtitle><date>2018-03-01</date><risdate>2018</risdate><volume>24</volume><issue>3</issue><spage>507</spage><epage>513</epage><pages>507-513</pages><issn>1083-8791</issn><issn>1523-6536</issn><eissn>1523-6536</eissn><abstract>•Outcome was studied of del 5q myelodysplastic syndrome patients undergoing allogeneic transplantation.•Patients with <5% bone marrow blasts and female recipients have the best prognosis.•Additional cytogenetic abnormalities do not influence the outcome.
The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P < .001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41 to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q) abnormality.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29196078</pmid><doi>10.1016/j.bbmt.2017.11.017</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-8791 |
| ispartof | Biology of blood and marrow transplantation, 2018-03, Vol.24 (3), p.507-513 |
| issn | 1083-8791 1523-6536 1523-6536 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_492209 |
| source | ScienceDirect Journals |
| subjects | Allogeneic stem cell transplantation del (5q) MDS Medicin och hälsovetenskap |
| title | Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T23%3A13%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Allogeneic%20Stem%20Cell%20Transplantation%20for%20Myelodysplastic%20Syndrome%20Patients%20with%20a%205q%20Deletion&rft.jtitle=Biology%20of%20blood%20and%20marrow%20transplantation&rft.au=Garderet,%20Laurent&rft.date=2018-03-01&rft.volume=24&rft.issue=3&rft.spage=507&rft.epage=513&rft.pages=507-513&rft.issn=1083-8791&rft.eissn=1523-6536&rft_id=info:doi/10.1016/j.bbmt.2017.11.017&rft_dat=%3Cproquest_swepu%3E1971681155%3C/proquest_swepu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c522t-b55f030d2d192ad416f78b575cbdaa7916661d91c7294a73a140554e4fe5245a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1971681155&rft_id=info:pmid/29196078&rfr_iscdi=true |